New GLP-1 Drugs Coming in 2026–2027: The Complete Pipeline Guide
From Wegovy HD to orforglipron to retatrutide - here is every new GLP-1 drug approved or in late-stage development, with timelines, weight loss data, and what patients need to know.
The GLP-1 drug landscape is changing faster in 2026 than in any previous year. Two drugs are already in FDA review, one approved yesterday, and others with extraordinary trial data are moving through Phase 3.
This guide covers everything that is approved or approaching approval - with real trial numbers, not just headlines.
ALREADY APPROVED IN 2025–2026
Wegovy Pill (oral semaglutide 25 mg)
FDA approved: December 22, 2025
The first oral GLP-1 medication approved specifically for weight loss. Daily tablet, same molecule as Wegovy injection.
- Weight loss: ~16.6% average at 64 weeks (OASIS 4 trial)
- Restriction: Must be taken on an empty stomach with max 120 ml water; 30-minute wait before eating
- Also approved for: Cardiovascular risk reduction in obesity + CVD
- Available now: Yes - NovoCare, Hims & Hers, 70,000+ pharmacies
Wegovy HD (semaglutide 7.2 mg)
FDA approved: March 19, 2026
The highest-dose Wegovy injection - for patients who need more from their GLP-1 therapy.
- Weight loss: ~21% average; one third of patients lost 25%+
- Format: Weekly injection, same as standard Wegovy
- Who it is for: Adults with obesity already tolerating semaglutide who want stronger results
- Available now: Yes
Zepbound for Sleep Apnea (tirzepatide)
FDA approved: December 20, 2024
First drug ever approved for obstructive sleep apnea. Tirzepatide reduces breathing disruptions per hour by approximately 62% alongside substantial weight loss.
- Indication: Moderate-to-severe OSA in adults with obesity
- Available now: Yes
Wegovy for Fatty Liver (MASH)
FDA approved (accelerated): August 15, 2025
First GLP-1 to receive approval for liver disease. Based on ESSENCE trial data showing MASH resolution and fibrosis improvement.
- Indication: Noncirrhotic MASH with F2–F3 fibrosis in adults
- Available now: Yes (using existing Wegovy 2.4 mg injection)
IN FDA REVIEW - EXPECTED 2026
Orforglipron (Eli Lilly)
NDA submitted: Late 2025 | FDA review: 2026
The biggest anticipated approval of 2026. A once-daily pill with no food restrictions - the first of its kind.
- Mechanism: Non-peptide small molecule GLP-1 receptor agonist
- Weight loss: Average 27.3 lbs (12.4%) at 40 weeks in ATTAIN-1 (obesity, no T2D)
- Key advantage: No injection, no fasting, no water restrictions - take any time
- Head-to-head: Beat oral semaglutide 14 mg by 73.6% more weight loss (ACHIEVE-3)
- Expected availability: Late 2026 pending FDA action
CagriSema (Novo Nordisk)
NDA submitted: December 18, 2025 | FDA review: 2026
A first-in-class combination of semaglutide (GLP-1) + cagrilintide (amylin analogue) in a single weekly injection.
- Mechanism: Amylin + GLP-1 dual action - two different appetite suppression pathways
- Weight loss: 22.7% at 68 weeks in REDEFINE 1 vs 2.3% placebo
- vs Semaglutide alone: 22.7% vs 16.1% - a meaningful improvement
- vs Tirzepatide: REDEFINE 4 showed 23% weight loss but did not achieve non-inferiority vs Zepbound 15 mg
- Expected availability: Late 2026 pending FDA action
PHASE 3 - EXPECTED 2027
Retatrutide (Eli Lilly)
Phase 3 (multiple trials) | Expected approval: 2027
The drug with the most extraordinary trial numbers in GLP-1 history.
- Mechanism: Triple agonist - GIP + GLP-1 + Glucagon receptors
- Weight loss: Average 71.2 lbs (32.3 kg) over 68 weeks at 12 mg (TRIUMPH-4, Phase 3)
- Phase 2: Up to 24.2% weight loss at 48 weeks
- Additional benefit: TRIUMPH-4 showed 75.8% reduction in knee osteoarthritis pain alongside weight loss
- Status: Main obesity Phase 3 results still pending; T2D Phase 3 met primary endpoint (March 2026)
- Note: Not available outside clinical trials
Oral Tirzepatide (Eli Lilly)
Phase 2 | Expected approval: 2027–2028
Oral pill version of tirzepatide - the same dual GIP+GLP-1 molecule in Mounjaro and Zepbound, formulated as a daily tablet.
- Status: Phase 2 trials ongoing
- Significance: Would bring Mounjaro-level efficacy to an oral format
PHASE 3 (2027 targets)
Survodutide (Boehringer Ingelheim + Zealand Pharma)
- Mechanism: GLP-1 + Glucagon dual agonist
- Phase 3 REVIVE trials ongoing - both obesity and MASH (fatty liver)
- Phase 2: ~19% weight loss
- Strong liver disease data may give it a differentiated position
AMG 133 / Maridebart Cafraglutide (Amgen)
- Mechanism: GLP-1 agonist + GIPR antagonist (novel - blocks GIP rather than activating it)
- Monthly injection - would be the first once-monthly GLP-1 option
- Phase 2: ~20% weight loss in 52 weeks
Pemvidutide (Altimmune)
- Mechanism: GLP-1 + Glucagon dual agonist
- Key angle: muscle preservation - designed to reduce fat-to-muscle ratio better than semaglutide
- Phase 2: ~15.6% weight loss with significantly less lean mass loss
DISCONTINUED
Danuglipron (Pfizer) - ❌ DISCONTINUED April 2025
Pfizer pulled its oral GLP-1 candidate after a patient experienced potential drug-induced liver injury in a dose-optimisation study. The program has been terminated.
How to compare the options
| Drug | Type | Frequency | Avg. weight loss | Status |
|---|---|---|---|---|
| Wegovy pill | Oral (fasting req.) | Daily | ~16.6% | ✅ Approved Dec 2025 |
| Wegovy HD | Injection | Weekly | ~21% | ✅ Approved Mar 2026 |
| Orforglipron | Oral (no restrictions) | Daily | ~10–12% | 🔄 FDA review |
| CagriSema | Injection | Weekly | ~22.7% | 🔄 FDA review |
| Retatrutide | Injection | Weekly | ~24–33% | Phase 3 |
| Oral tirzepatide | Oral | Daily | TBD | Phase 2 |
| AMG 133 | Injection | Monthly | ~20% | Phase 2 |
What this means for current GLP-1 users
The landscape is expanding rapidly. Within 12–18 months:
- There will be multiple oral GLP-1 options at different price points
- Injectable options will offer significantly stronger weight loss than today
- A monthly injection may eventually reduce the logistical burden of weekly dosing
If you are currently on Ozempic, Wegovy, Mounjaro, or Zepbound and satisfied with your results, there is no reason to wait. But if you have plateaued or want stronger efficacy, the pipeline options coming in 2026–2027 are worth following.
WeightEasy will support all newly approved GLP-1 drugs as they become available, so your dose tracking, symptom logs, and weight trends carry seamlessly across medication changes.
Final takeaway
2026 is the most active year in GLP-1 drug development. Two drugs are already approved in the past few months (Wegovy pill, Wegovy HD), two are in FDA review (orforglipron, CagriSema), and one pipeline drug (retatrutide) has produced the highest average weight loss ever recorded in a clinical trial. The options available to patients will look very different by the end of 2027.
Consult your healthcare provider about which option is most appropriate for your situation.
Sources
- Wegovy FDA approval history: drugs.com/history/wegovy.html
- Orforglipron history: drugs.com/history/orforglipron.html
- CagriSema history: drugs.com/history/cagrisema.html
- Retatrutide history: drugs.com/history/retatrutide.html
- ATTAIN-1 results: N Engl J Med, September 2025
- ACHIEVE-3 results: The Lancet, February 2026
- REDEFINE 1 results: Novo Nordisk press release, December 2024
- TRIUMPH-4 results: Eli Lilly press release, December 2025
FAQ
What new GLP-1 drugs are coming in 2026?
The two most imminent approvals in 2026 are orforglipron (Eli Lilly's once-daily oral GLP-1 pill, NDA under review) and CagriSema (Novo Nordisk's amylin + semaglutide combination, NDA under review). Wegovy HD (7.2 mg) was already approved in March 2026, and the Wegovy pill was approved in December 2025.
What is the most powerful new GLP-1 drug?
Retatrutide (Eli Lilly's triple agonist) produced the highest average weight loss ever recorded in a drug trial - 71.2 lbs (32.3 kg) over 68 weeks. It is still in Phase 3 and is not expected before 2027.
Will there ever be a GLP-1 drug with no injection and no food restrictions?
Yes - orforglipron is expected to be approved in 2026. It is a non-peptide small molecule taken once daily as a pill with no fasting or food restrictions. It is the first GLP-1 with this profile.
Is oral semaglutide (Wegovy pill) the same as orforglipron?
No. Both are daily oral GLP-1 medications, but they are different molecules. Wegovy pill (oral semaglutide 25 mg) requires fasting and water-only intake for 30 minutes after taking it. Orforglipron is a small molecule with no food restrictions. They were also compared head-to-head: orforglipron significantly outperformed oral semaglutide 14 mg in a clinical trial.